Bisphosphonate treatment may reduce osteoporosis risk in female cancer patients with morphine use: a population-based ne
- PDF / 157,112 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 14 Downloads / 167 Views
ORIGINAL ARTICLE
Bisphosphonate treatment may reduce osteoporosis risk in female cancer patients with morphine use: a population-based nested case–control study C. W.-S. Lee & C.-H. Muo & J.-A. Liang & S.-N. Chang & Y.-J. Chang & C.-H. Kao
Received: 31 January 2013 / Accepted: 21 February 2013 / Published online: 8 March 2013 # International Osteoporosis Foundation and National Osteoporosis Foundation 2013
Abstract Summary Chronic use of morphine is a risk factor for endocrinopathy and osteoporosis. Bisphosphonates accentuated the protective effect to develop osteoporosis in female patients with malignancy with morphine treatment. Introduction This study investigates the risk of osteoporosis associated with morphine use by comparing the incidence of
C. W.-S. Lee Center for Drug Abuse and Addiction, China Medical University Hospital, Taichung, Taiwan, Republic of China C. W.-S. Lee College of Medicine, China Medical University, Taichung, Taiwan, Republic of China C.-H. Muo : S.-N. Chang : Y.-J. Chang Department of Public Health, China Medical University, Taichung, Taiwan, Republic of China C.-H. Muo : S.-N. Chang : Y.-J. Chang Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan, Republic of China J.-A. Liang : Y.-J. Chang : C.-H. Kao (*) Graduate Institute of Clinical Medicine Science, College of Medicine, China Medical University, No. 2, Yuh-Der Road, Taichung 40447 Taiwan, Republic of China e-mail: [email protected] C.-H. Kao e-mail: [email protected]
osteoporosis in female cancer patients treated with and without morphine. Methods A population-based nested case–control retrospective analysis was performed using the Longitudinal Health Insurance Database 2000 and Registry for Catastrophic Illness Patients of Taiwan. A malignancy cohort of 12,467 female patients without a history of osteoporosis during 1998–2010, and then 639 patients who subsequently developed osteoporosis as the osteoporosis group, were evaluated. Control-group patients were selected from the malignancy cohort without osteoporosis and frequency matched to each osteoporosis case 2:1 for age, year of cancer diagnosis, and index year. Logistic regression was used to estimate the odds ratios and 95 % confidence intervals, and the multivariable model was applied to control for age. Results Female cancer patients who received morphine had a 10 % lower risk of developing osteoporosis than nonmorphine users, but this risk reduction was not significant. For patients treated with bisphosphonates, the morphine group had significantly lower odds in developing osteoporosis than the non-morphine group. Conclusion Morphine treatment is not associated with the incidence of osteoporosis, and bisphosphonates accentuated the protective effect of morphine in the development of osteoporosis in female patients with malignancy in Taiwan. Keywords Bisphosphonates . Cancer . Morphine . Osteoporosis
J.-A. Liang Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan, Republic of China
Intro
Data Loading...
